Cassava Sciences Inc(SAVA)stock report

Cassava Sciences, Inc., formerly Pain Therapeutics, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing drug for the treatment of nervous system disorders. The Company is ocused on the early detection and treatment of neurodegenerative diseases, such as Alzheimer’s. Its drug candidate, PTI-125, is a small molecule that targets an altered form of a scaffolding protein called filamin A (FLNA). The Company is also developing an experimental biomarker/diagnostic, PTI-125Dx. It is developing PTI-125Dx to detect Alzheimer’s disease with a blood test.

Finance:
Market Cap:73.5M; Shares Outstanding:9.2M; Short Interest: 15.46%; Q3 2019(9/30/19): Cash 17.8M. Loss 0.7M

EPS and Sales:
https://finance.yahoo.com/quote/SAVA/financials?p=SAVA

Date EPS % last year % last quarter
2018.12.31 -0.61 66.48% -11.59%
2019.3.31 -0.0789 74.81% 87.07%
2019.6.31 -0.1404 79.01% 1.74%
2019.9.30 -0.18 73.91% -28.21%

 

Sales:0

Insider Transactions:
http://insidercow.com/history/company.jsp?company=SAVA&B1=Search%21

Institution Ownership:
https://www.marketbeat.com/stocks/NYSE/SAVA/institutional-ownership/

2019.12.08:
Total institutions: 29,no change
Shares hold: 1825.1k shares. no change
shares% hold: 10.6%,no change

Analyst Ratings:
https://www.tipranks.com/stocks/SAVA/price-targe

News:

2019-12-6: Cassava up 41% premarket on encouraging data on PTI-125 in Alzheimer’s

2019-10-29: Cassava Sciences Announces Recent Clinical Highlights and Third Quarter 2019 Financial Results

2019-9-16: Cassava Sciences (SAVA) Presents At H.C. Wainwright 21st Annual Global Investment Conference – Slideshow

Leave a Reply